Company news

Ac Immune Sa (NASDAQ:ACIU) news

Ac Immune Sa news releases on 6ix. Latest, Aug 11, 2026: AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy…

Ac Immune Sa (NASDAQ:ACIU) news

Press releases & updates

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

AC Immune to Present at the Jefferies 2025 London Healthcare Conference

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune to Participate in Upcoming Investor Conferences

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic